Recursion Pharmaceuticals Inc. (RXRX) News

Recursion Pharmaceuticals Inc. (RXRX): $9.64

0.27 (+2.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RXRX News Items

RXRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RXRX News Highlights

  • RXRX's 30 day story count now stands at 5.
  • Over the past 7 days, the trend for RXRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG, MAPS and MO are the most mentioned tickers in articles about RXRX.

Latest RXRX News From Around the Web

Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.

Recursion to Participate in Upcoming Investor Conference

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:

Yahoo | February 1, 2023

Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Recursion Pharmaceuticals (RXRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | January 27, 2023

Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced the public release of MolRec™ - one of its many interactive internal tools to explore the company's proprietary maps of biology and chemistry. Just as a regular map is a navigation tool in the physical world, Recursion's maps are designed to help scientists understand the topology and connectedness of human biology and chemistry to navigate the path to new medicines mo

Yahoo | January 26, 2023

Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?

Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 25, 2023

How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%

The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 25, 2023

Institutional investors may adopt severe steps after Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) latest 7.4% drop adds to a year losses

To get a sense of who is truly in control of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ), it is important to...

Yahoo | December 28, 2022

Recursion to Participate in Upcoming Investor Conferences

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:

Yahoo | December 20, 2022

Forecast: Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Business Prospects Have Improved Drastically

Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) shareholders will have a reason to smile today, with the analysts...

Yahoo | November 17, 2022

Recursion Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

Recursion Pharmaceuticals ( NASDAQ:RXRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.2m (up 419...

Yahoo | November 10, 2022

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.668 seconds.